Aravive Investor Presentation Deck

Exposure-Response Modeling Consistent with Preclinical Data Exposure-Response modeling of P1b PROC and P1b ccRCC demonstrates a plateau at 20mg/kg Preclinical data from ovarian cancer model demonstrated plateau from 10 to 20mg/kg (equate to lower doses in humans) - No toxicity issues identified No inverted U shape response No evidence of tachyphylaxis or hormesis Tumor Number Skovdupovarian in vivo study 5 mg/kg and 10 mg/kg tumor number 200 154 100 P85 Contrat -P00067 580 Smok Group # 500 tingk PBS AVB-S6-500 (5mg/kg) AVB-S6-500 (10mg/kg) Group # Tumor Number 150- 100- Skov3.ip ovarian in vivo study 20mg/kg tumor number PBS Control PBS AVB-S6-500 (20mg/kg) Data from report PHARM-010 Number Weight (g) average SEM average SEM 76.22 11.63 1.062 0.081 60.89 7.052 1.084 0.101 500c 20mg g 38.56 5.87 Number average SEM 0.768 0.091 Weight (g) average SEM 75.67 9.541 1.029 0.082 40.22 8.642 0.883 0.102 +P-0.014 15

View entire presentation